The global Graves Disease (Overactive Thyroid) sector is witnessing steady growth as diagnosis rates improve, healthcare infrastructure expands, and pharmaceutical companies invest in safer and more targeted therapies. The sector was valued at USD 2.26 billion in 2025 and is projected to reach USD 2.37 billion in 2026 and approximately USD 3.69 billion by 2035, expanding at a CAGR of 5.02% from 2026 to 2035.
Rising awareness of thyroid disorders, routine thyroid testing, increasing patient numbers, and advances in autoimmune disease research are supporting continued expansion.
Download a Sample Report: https://www.precedenceresearch.com/sample/7878
Compact Scope Table
| Report Coverage | Details |
|---|---|
| 2025 Value | USD 2.26 Billion |
| 2026 Value | USD 2.37 Billion |
| 2035 Value | USD 3.69 Billion |
| CAGR 2026-2035 | 5.02% |
| Leading Region | North America |
| Fastest-Growing Region | Asia Pacific |
| Leading Treatment | Antithyroid Medications |
| Leading Diagnosis Method | Blood Test |
| Leading End User | Hospitals |
| Key Opportunity | Targeted Therapies and Advanced Diagnostics |
Diagnosis Remains the Foundation of Care
The initial diagnosis segment held the leading position in 2025 as patients seek medical attention after experiencing symptoms such as rapid heartbeat, fatigue, anxiety, and unexplained weight loss.
Blood testing remained the leading diagnostic method because TSH, T3, T4, and antibody tests are widely available and relatively accessible. Regular testing also supports long-term monitoring and treatment adjustments.
Treatment Innovation Is Creating New Opportunities
Antithyroid medications led treatment demand in 2025 due to their established use, affordability, and non-invasive administration. However, radioactive iodine therapy is expected to experience strong growth as it provides a long-term treatment option for selected patients.
Pharmaceutical research is increasingly focused on therapies that target the autoimmune mechanisms behind Graves Disease (Overactive Thyroid), creating opportunities for more precise and personalized treatment.
AI Is Advancing Thyroid Care
Artificial intelligence is introducing new capabilities in diagnosis, monitoring, and therapeutic research. AI-powered systems can analyze thyroid function data, identify abnormal hormone patterns, and support interpretation of imaging results.
Machine learning can also help researchers evaluate large datasets to identify factors linked to treatment response and relapse. These technologies could improve clinical efficiency while supporting more personalized disease management.
North America Leads While Asia Pacific Accelerates
North America accounted for approximately 40% of the global share in 2025. The regional sector is projected to increase from USD 904 million in 2025 to around USD 1.45 billion by 2035, expanding at a 5.16% CAGR.
Strong healthcare infrastructure, high diagnosis rates, access to advanced treatment, and substantial research activity support the region’s leadership.
Asia Pacific is expected to experience the fastest growth as healthcare access improves and awareness of thyroid disorders increases across countries such as China, India, and Japan.
Companies Are Advancing the Competitive Landscape
Leading organizations including Abbott Laboratories, Roche, Pfizer, Novartis, Sanofi, Teva Pharmaceutical Industries, Merck KGaA, Immunovant, Viridian Therapeutics, Sling Therapeutics, and Amgen are contributing to diagnostics, treatment development, autoimmune research, and patient care.
Growing investment in targeted therapies and advanced diagnostics is expected to strengthen innovation across the sector.
The Road Ahead
The future of Graves Disease (Overactive Thyroid) care will increasingly focus on earlier diagnosis, long-term monitoring, targeted therapies, advanced diagnostics, and AI-supported healthcare.
As treatment innovation progresses and healthcare systems improve access to specialized thyroid care, the sector is positioned for steady expansion through 2035.
Buy this report: https://www.precedenceresearch.com/checkout/7878
About Us
Healthcare Prism is a dedicated healthcare insights and outreach platform, operating as an extension of Precedence Research. We share relevant perspectives, industry developments, emerging trends, and research-driven insights across the global healthcare sector. Our content is built on the knowledge, research standards, and expertise of Precedence Research, with a focus on making healthcare information clear, accessible, and useful for industry professionals, businesses, researchers, and healthcare stakeholders. Healthcare Prism serves as a focused platform to extend the reach of Precedence Research’s healthcare insights and connect them with a broader professional audience.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Quick Contact:
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04 and +65 31065601
Visit Our Website: Precedence Research – Advisory, Research & Reports